Cargando…

Circulating clonally expanded T cells reflect functions of tumor-infiltrating T cells

Understanding the relationship between tumor and peripheral immune environments could allow longitudinal immune monitoring in cancer. Here, we examined whether T cells that share the same TCRαβ and are found in both tumor and blood can be interrogated to gain insight into the ongoing tumor T cell re...

Descripción completa

Detalles Bibliográficos
Autores principales: Lucca, Liliana E., Axisa, Pierre-Paul, Lu, Benjamin, Harnett, Brian, Jessel, Shlomit, Zhang, Le, Raddassi, Khadir, Zhang, Lin, Olino, Kelly, Clune, James, Singer, Meromit, Kluger, Harriet M., Hafler, David A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Rockefeller University Press 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7933991/
https://www.ncbi.nlm.nih.gov/pubmed/33651881
http://dx.doi.org/10.1084/jem.20200921
Descripción
Sumario:Understanding the relationship between tumor and peripheral immune environments could allow longitudinal immune monitoring in cancer. Here, we examined whether T cells that share the same TCRαβ and are found in both tumor and blood can be interrogated to gain insight into the ongoing tumor T cell response. Paired transcriptome and TCRαβ repertoire of circulating and tumor-infiltrating T cells were analyzed at the single-cell level from matched tumor and blood from patients with metastatic melanoma. We found that in circulating T cells matching clonally expanded tumor-infiltrating T cells (circulating TILs), gene signatures of effector functions, but not terminal exhaustion, reflect those observed in the tumor. In contrast, features of exhaustion are displayed predominantly by tumor-exclusive T cells. Finally, genes associated with a high degree of blood–tumor TCR sharing were overexpressed in tumor tissue after immunotherapy. These data demonstrate that circulating TILs have unique transcriptional patterns that may have utility for the interrogation of T cell function in cancer immunotherapy.